SALL4 is aberrantly expressed in human myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). We have generated a SALL4 transgenic (SALL4B Tg) mouse model with pre-leukemic MDS-like symptoms that transform to AML over time. This makes our mouse model applicable for studying human MDS/AML diseases. Characterization of the leukemic initiation population in this model leads to the discovery that Fancl (Fanconi anemia, complementation group L) is downregulated in SALL4B Tg leukemic and pre-leukemic cells. Similar to the reported Fanconi anemia (FA) mouse model, chromosomal instability with radial changes can be detected in pre-leukemic SALL4B Tg bone marrow (BM) cells after DNA damage challenge. Results from additional studies using DNA damage repair reporter assays support a role of SALL4 in inhibiting the homologous recombination pathway. Intriguingly, unlike the FA mouse model, after DNA damage challenge, SALL4B Tg BM cells can survive and generate hematopoietic colonies. We further elucidated that the mechanism by which SALL4 promotes cell survival is through Bcl2 activation. Overall, our studies demonstrate for the first time that SALL4 has a negative impact in DNA damage repair, and support the model of dual functional properties of SALL4 in leukemogenesis through inhibiting DNA damage repair and promoting cell survival.
INTRODUCTION SALL4, a zinc-finger transcription factor of the SALL gene family, has been isolated based on its homology to a Drosophila region-specific homeotic gene, spalt. Human SALL4 mutations are associated with Duane-radial ray syndrome (or Okihiro syndrome). [1] [2] [3] [4] This condition is an autosomal dominant disorder involving radial-sided hand anomalies in association with Duane syndrome, which is a congenital disorder of eye movement characterized by strabismus. In addition, a novel SALL4 mutation has been identified in a large IVIC (Instituto Venezolano de Investigaciones Cientìficas) syndrome family by the Arias group. 5 The IVIC syndrome is an autosomal dominant condition with Duane-radial ray syndrome, leukocytosis and thrombocytopenia, which suggests that SALL4 may have a role in normal hematopoiesis. 5 This observation has been further supported by additional studies. 6 Knocking down SALL4 in normal human CD34+ hematopoietic stem/progenitors leads to impaired hematopoietic differentiation, 6 and SALL4 has a role in normal human hematopoiesis by affecting genes implicated in hematopoietic cell proliferation and differentiation such as HOXA9 and RUNX1. 6 In addition to its role in human development, SALL4 is an essential factor for embryonic stem (ES) cells. In recent years, multiple research groups, [7] [8] [9] including ours, 10 have demonstrated that SALL4 has an essential role in the maintenance of ES cell pluripotency and self-renewal by interacting with other two key regulators in ES cells, Nanog and Oct4. Loss of SALL4 expression in ES cells results in the downregulation of ES cell makers, such as Oct4, and spontaneous ES cell differentiation.
Whereas SALL4 expression is downregulated during development, and not detectable in most human adult tissues, it is aberrantly expressed in high-grade myelodysplastic syndrome (MDS) patients 11 and most acute myeloid leukemia (AML) patients. 12 Loss-of-function studies have demonstrated that SALL4 is essential for leukemic survival, 13, 14 and SALL4 is being investigated as a new target in treating human MDS and AML. Direct evidence of the causative role of SALL4 in leukemogenesis has been demonstrated by studies from our laboratory in SALL4 transgenic (SALL4B Tg) mice, which developed pre-leukemic MDSlike features before subsequent AML transformation, 12 making this murine model relevant to study human MDS/AML progression. Therefore, we aim to use this Tg model to study the mechanisms by which SALL4 promotes the progression from MDS to AML.
In this study, through gene expression profiling, we found Fancl (Fanconi anemia, complementation group L) to be downregulated in leukemia-initiating population as well as in the pre-leukemic bone marrow (BM) cells in the SALL4B Tg mice. Fancl is a component of the FA (Fanconi anemia) protein complex. Defects of the FA protein complex can lead to defective DNA damage repair. We tested the DNA damage repair capacity of SALL4B Tg BM cells after challenge with the DNA-damaging agent Mitomycin C (MMC) as well as by the use of homologous recombination (HR) and nonhomologous DNA end joining (NHEJ) reporter assays. Our results suggest that SALL4 can contribute to defective DNA damage repair through inhibition of the HR pathway. In addition, we found that Bcl2 (B-cell lymphoma 2) was upregulated in the SALL4B Tg pre-leukemic BM cells, which contributes to enhanced survival of these cells. Overall, in this report, we have explored the role of SALL4 in DNA damage repair and cell survival after DNA damage challenge and our findings provide new insight into SALL4-mediated leukemogenesis.
RESULTS
Fancl was downregulated in SALL4B Tg leukemic and pre-leukemic cells In normal human BM samples, SALL4B is expressed preferentially in the CD34+CD38 − hematopoietic stem cells, and is downregulated significantly in the CD34+CD38+ hematopoietic progenitor cells (HPCs). 6 By contrast, in leukemic samples, SALL4B is expressed at a higher level in the CD34+CD38+ HPCs than that in the CD34+CD38 − hematopoietic stem cells. 15 We previously reported the generation of SALL4B Tg mouse model. 12 In this study, we further evaluated the pattern of SALL4B expression in these mice. We observed that SALL4B was expressed at a higher level in HPC populations than in phenotypically defined Lin-Sca-1+ c-kit+ (LSKs, Supplementary Figure 1 ) enriched for hematopoietic stem cells. This aberrant expression pattern of SALL4 is similar to what we have observed in human leukemia. 15 On the basis of previous data from these transgenic mice, 12 we defined the pre-leukemic phase from 2 months until evolution of frank leukemia defined as leukemic phase, which usually occurred by 8 months. To determine whether the MDS-like cellular defect contributing to the leukemic phenotype originated at the stem or progenitor cell compartment, we analyzed the LSK and HPC subpopulations and correlated the numbers with the disease progression in SALL4B Tg mice. The total number of BM cells was similar among wild-type (WT), SALL4B Tg pre-leukemic and leukemic animals. The percentages of both LSK and HPC populations were elevated significantly for pre-leukemic and leukemic stages in the SALL4B Tg mice compared with WT littermates (Supplementary Figure 2) . The LSK and granulocytemacrophage progenitor (GMP) cell populations were further expanded as the disease proceeded from the pre-leukemic to leukemic stages (Supplementary Figure 2) . To identify which population can initiate the leukemic phenotype in a transplant model, we sorted the LSK and HPC sub-populations from primary leukemic SALL4B Tg donor mice and performed serial leukemic transplantations using a NOD-SCID mouse model as previously reported. 12 As shown in Table 1 , both LSKs and GMP cells gave rise to the leukemic phenotype in the recipients, indicating that both populations contain leukemia initiation activity.
To investigate the molecular mechanism of SALL4's role in the development of leukemia, and to characterize the genetic changes that occur during the transition from normal hematopoietic cell to leukemia-initiating cells (LIC), we isolated the Leukemia (L)-GMPs and L-LSKs from three independently transplanted NOD-SCID recipients, and then compared their gene expression profiles to those populations isolated from preleukemic SALL4B Tg mice, control NOD-SCID (NOD) and WT littermates. Unsupervised analysis demonstrated that the global gene expression profiles of SALL4-GMPs (L-GMP and P-GMP) or LSKs (L-LSKs and P-LSK) were similar to those from the respective controls (NOD-GMP and WT-GMP or NOD-LSK and WT-LSK) (Figure 1a) .
Further analysis using dChip revealed an expression signature for the L-LSK, which consists of both upregulated (93 probe sets) and downregulated genes (341 probe sets). Similarly, an expression signature for the L-GMP consisted of upregulated (83 probe sets) and downregulated genes (394 probe sets). There were 36 dysregulated genes shared between these two LIC populations (Figure 1b and Supplementary Table 2 ). Among these, the altered expression of several potentially relevant genes was verified by qRT-PCR. In the SALL4B L-LSK population, Fancl (P o0.001), p18 (P = 0.044), Caspase 6 (P = 0.015) and Notch1 (P o0.001) were all downregulated when compared with those from control WT LSKs. In L-GMPs, Fancl (P o 0.001), Foxo3a (P o 0.001) and Myadm2 (P o 0.001) were confirmed to be downregulated when compared with those from control WT GMPs. Thus, Fancl was downregulated in both LIC populations (Figure 1c) .
FANCL belongs to the FA protein complex. FA is an inherited BM failure syndromes resulting from deficiency or mutation of one of 19 proteins (FA complementation groups A, B, C, D1, D2, E, F, G, I, J, L, M, N, O, P, Q, R, S and T, http://www.rockefeller.edu/fanconi/) that are involved for DNA repair. As a result, 20% or more of FA patients develop cancer, most often AML, and 90% of those develop BM failure and/or some features of MDS by the age of 40. 16 Thus, we hypothesized that the pre-leukemic and MDS phenotypes of SALL4B Tg mice was linked to reduced Fancl expression. To test this hypothesis, we examined the expression of Fancl by quantitative real-time RT-PCR in five pairs of BM cells from age-matched WT and SALL4B pre-leukemic Tg mice. Fancl expression was significantly downregulated in SALL4B preleukemic Tg mice when compared with that of WT (Figure 1d ). SALL4B Tg mice had HR deficiency but not NHEJ in DNA damage repair FANCL is an E3 Ubiquitin ligase protein that mediates the monoubiquitination of FANCD2, a key step in activating the downstream FA pathway that triggers the subsequent DNA damage repair process. To determine whether SALL4 has a role in DNA damage repair through its role in regulating Fancl, we utilized HR and NHEJ reporter systems [17] [18] [19] [20] [21] to explore the effect(s) of SALL4 expression on specific DNA damage repair pathway(s). We first created DNA double-strand breaks in cells transfected with HR or NHEJ reporter cassette in vitro by I-SceI restriction digest. As shown in Figure 2a , the HR repair efficiency was During the primary transplants, there were two cases of CMP and MEP donor cells that caused leukemic phenotypes in the recipient mice. However, fluorescence-activated cell-sorting analysis analysis was performed on the leukemic recipients before the secondary transplant and showed only GMP population present, which suggested that these CMP and MEP cases were contaminated with GMPs. SALL4B Tg mice displayed chromosomal instability after MMC treatment Cells defective in the FA pathway display an increased frequency of chromosomal breaks after challenged with the DNA crosslinking drug MMC 22 and chromosome aberrations such as chromatid interchange triradial and quadriradial are typically observed in MMC-treated cells from FA patients 23 or FA mice. 24 As the SALL4B Tg mice showed decreased Fancl expression level, we next examined whether SALL4B Tg pre-leukemic mice had an unstable chromosomal phenotype after MMC challenge. SALL4B Tg mouse BM cells displayed typical FA-like chromosomal abnormalities such as chromatid interchange radial changes at a rate of 10-15 per 50 counted cells (Figures 2b and c) after MMC treatment, while cells from WT mice showed no visible chromosomal abnormalities. Intriguingly, older (48 month) SALL4 Tg mice had statistically significantly more abnormal chromosomal abnormalities per cell than the younger SALL4 Tg mice (⩽8 month) after MMC challenge (Supplementary Figure 6) . High SALL4 expression level was correlated with complex karyotype in MDS/AML patients To examine whether SALL4 is also involved in chromosomal instability in human primary MDS/AML patients, we evaluate the correlation between SALL4 expression and chromosome karyotypes of these samples. Using publicly available datasets (GSE13159), 25, 26 we found that the expression of SALL4 in AML patients with complex karyotype (equal to or more than three aberrant karyotypes) was significantly higher (P = 0.0186) than that in MDS patients with normal karyotype (Figure 3a) . In addition, reanalysis of our prior collection of MDS patient samples 11 showed that higher SALL4 RNA (Figure 3b ) and protein (Figure 3c ) expression in MDS patients was associated with the complex karyotype.
As TP53 mutation/alternation is the most common biomarker associated with complex karyotype in human MDS patients, 27 we next examined whether there was an association between SALL4 expression and TP53 mutation. As TP53 mutation in cancer cells leads to prolonged half-life of the protein, immunohistochemistry has been used to detect mutant TP53. 28 Twenty MDS cases were selected for the evaluation of SALL4 expression and TP53 mutation. Overall, 16 out of 20 cases (80%) showed consistency for TP53 and SALL4 based on the positive or negative immunohistochemistry results (Table 2 and Supplementary  Figure 7 ). SALL4 expression was positively correlated with TP53 expression/mutation in these MDS patients (contingency coefficient r = 0.52, P o 0.05). Future study with a larger cohort of MDS patients is required to validate this result. SALL4B Tg mice BM cells had increased Bcl2 expression Similar to other mouse models of FA, Fanca − / − mice demonstrate hypersensitivity to BM damage with increased stressinduced apoptosis and reduced marrow progenitor cells after MMC treatment. 29 To evaluate whether SALL4B Tg mice showed a similar phenotype, we performed colony-forming unit assays after MMC treatment of both SALL4B Tg and Fanca − / − BM cells. Surprisingly, despite our observation of abnormal chromosomal changes after MMC treatment in our SALL4B Tg pre-leukemic BM cells (Figure 2c ), unlike the Fanca − / − mice, we observed no increased sensitivity to MMC, with colony-forming unit colonies in SALL4B Tg BM cells even at concentrations as high as 20 nM (Figure 4a ). One explanation for this difference in response to MMC is the possibility that SALL4B cells express increased antiapoptosis signals. To explore this hypothesis, we next performed gene expression profiling on SALL4B Tg pre-leukemic BM cells. Overall, 67 genes were upregulated, and 55 genes were downregulated in SALL4B Tg pre-leukemic BM cells when compared with the WT controls (Supplementary Table 3 ). A comparison with the gene expression profiles of SALL4B Tg pre-leukemic BM cells with our previous studies on human CD34+ cells 6 revealed that BCL2 was the overlap gene in both data sets (Figure 4b and Supplementary table 4) , suggesting that BCL2 is a conserved target of SALL4 in mice and human. We further confirmed the microarray data by qRT-PCR assay and showed that Bcl2 expression was significantly increased in SALL4B Tg mouse BM cells compared with WT controls (P = 0.0111) (Figure 4c) . Similarly, overexpressing SALL4 in KBM5 cells led to increased BCL2 expression with decreased FANCL expression (Supplementary Figure 8) .
To further confirm that changes in Bcl2 mRNA results in functional alterations, we treated mouse BM cells with a BCL2 inhibitor ABT-737 and MMC and performed colony-forming unit assays. The number of colonies from SALL4B Tg BM cells treated with both MMC and ABT-737 were significantly higher than that from WT controls treated similarly (Figure 4d and Supplementary  Figure 9 ). Together, these results suggest that SALL4 promotes cell survival in part through the BCL2 pathway.
DISCUSSION
Human MDS is a group of clonal hematopoietic stem cell disorders characterized by cellular dysplasia and refractory cytopenias as a result of ineffective hematopoiesis. MDS is mostly seen in the elderly, with over 10 000 new cases per year in the US alone. As the population ages, the role of this disease in limiting life expectancy will become more significant. About 30-40% of MDS patients progress to AML with a poor prognosis and short life expectancy. However, it remains unclear what mechanism(s) drives the progression of MDS to AML, the understanding of which will enable development of novel strategies in treating these patients. Few murine models have been generated that mimic human MDS/AML disease progression. We have previously reported that SALL4 is aberrantly expressed in human MDS/ AML, 11, 12 and SALL4B Tg mice develop MDS-like features before progressing to AML. 12 Therefore, we propose to use the SALL4B Tg murine model to search for novel insight(s) in this human disease.
Here, we first explored the role of SALL4 in leukemogenesis by monitoring the changes of gene expression profiles from the hematopoietic sub-populations and LIC populations during disease progression in the SALL4B Tg mouse model. Thirty-six genes are shared by these two LIC populations, one of which is Fancl, a gene that encodes an E3 ubiquitin ligase in the FA protein complex, which has a crucial role in DNA repair and genomic stability maintenance. 30, 31 Interestingly, deregulation of FANCL has been reported in AML patients. 32, 33 We demonstrated that the expression of Fancl is significantly downregulated in pre-leukemic SALL4B Tg mouse BM cells. SALL4 probably affects the expression of FANCL gene indirectly because no binding peaks were observed at the promoter region of this gene in our previous global ChIPChip studies. 6, 14 Several FA mouse models are available that share a phenotype of mild ineffective hematopoiesis and hypersensitive to the DNA cross-linking agent MMC. 22, 34, 35 In the SALL4B Tg mouse model, we have observed abnormal chromosomal changes after MMC treatment that are similar to those seen in FA mice that correlated with decreased Fancl expression. We also demonstrate using reporter assays that HR DNA damage repair pathway is deficient in SALL4B Tg mouse BM cells. Similar results that correlate SALL4 expression with chromosomal abnormalities were also observed in human samples as primary MDS and AML Our previous study demonstrated that SALL4 has a key role in leukemic cell survival by affecting multiple pathways, including the direct activation of anti-apoptotic gene Bcl2.
14 Our current study demonstrated that Bcl2 is upregulated in SALL4B Tg preleukemic mice, which may account for the enhanced survival of BM progenitors of SALL4B Tg cells after MMC treatment because these cells are more resistant to the BCL2 inhibitor ABT-737 treatment.
In summary, our studies indicate that SALL4 can negatively affect the DNA damage repair processes, at least in part, through repressing Fancl. In addition, SALL4 can promote cell survival by activating the anti-apoptosis gene Bcl2. Taken together, it is possible that the SALL4B Tg mice are more prone to accumulate secondary mutations, which may lead to their progression from MDS into the AML stage. Overall, our studies suggest that SALL4 has dual functional roles in inhibiting DNA damage repair and promoting cell survival following genotoxic stress. Our findings provide novel insight on the pathogenesis of SALL4 in MDS/AML disease progression.
MATERIALS AND METHODS
Mice and serial transplantation SALL4B Tg mice were generated as previously described. 12, 36 Both male and female mice, age from 3 months to 12 months were used. Serial transplantation was also previously described. 36 Briefly, whole BM, spleen, sorted LSKs (Lin-Sca-1+c-kit+), common myeloid progenitors (Lin-Sca-1-ckit+CD34 + FcγRII/III low ), GMPs (Lin-Sca-1-c-kit+CD34 + FcγRII/III + ) and megakaryocyte erythroid progenitors (Lin-Sca-1-c-kit+CD34
− FcγRII/III − ) from SALL4-induced leukemic mice or primary recipient mice were transplanted into NOD/SCID mice by tail vein injection. The transplantation cell-dose ranges were shown in Table 1 . The Fanca knockout mice were described previously. 29 All animal work has been conducted in accordance to relevant national and international guidelines, as well as the recommendations of the Weatherall report, and the mice are housed at Children's Hospital Boston. The sample size estimate is based on a 80% predication power, with a 0.05 significance level to detect a 1.00 s.d. difference between the two study groups. Randomization or blinding is not applicable to our studies.
Fluorescence-activated cell-sorting analysis
Hematopoietic stem and progenitor cells were isolated from mouse BM cells as described previously. 37 Briefly, mouse BM cells were stained for the following antibodies: Lineage marker (CD3, CD4, CD8, Gr-1, CD19, B220 and Ter119) (Invitrogen, Caltag Laboratories, Carlsbad, CA, USA), Sca-1, c-kit, CD34 and FcγR (Fc gamma receptors) II/III (BD Biosciences PharMingen, San Diego, CA, USA). After 30 min staining at 4°C, cells were washed three times with phosphate-buffered saline (PBS) and resuspended in 1 × PBS with 2% heat-inactivated fetal bovine serum and 1 μg/ml propidium iodide. Then, the cells were analyzed or sorted using MoFlo cell sorter (Dako, Fort Collins, CO, USA).
Polymerase chain reaction (PCR) and quantitative reverse transcription-PCR (qRT-PCR)
PCR and qRT-PCR were performed as previously described. 12 Briefly, a PCR kit (Qiagen, Valencia, CA, USA) was used to genotype the SALL4B Tg founder mice and transmission of the transgene. Genomic DNA was purified from a mouse tail using a high-quality DNA kit (Gentra Systems, Minneapolis, MN, USA). The human SALL4B primer sequences were shown in Supplementary Table 1. Total RNA was isolated using a phenol-free and filter-based RNA isolation system (Qiagen) digested with DNase I to remove DNA contamination. Primer sequences for qRT-PCR were designed using Primer Express software (Applied Biosystems, Foster City, CA, USA) and were listed in Supplementary Table1. All reactions were performed in an ABI-7000 sequence detection system using TaqMan PCR core reagents according to the manufacturer's instructions (Applied Biosystems). PCR amplification was carried out in a 50 μl final volume containing 1 × PCR buffer, 1 μM of each primer and 10 μl of RNA at 95°C for 10 min followed by 45 cycles at 95°C for 15 s and then at 60°C for 1 min. For each sample, expression of the GAPDH gene was used to normalize the amount of investigated transcript.
Gene expression profiling
Total RNA of various populations or whole BM cells (2-5 × 10 4 cells per population) from WT, NOD-SCID and the NOD-SCID mice with leukemic cell transplants was extracted using Trizol reagent (Invitrogen Corp, Carlsbad, CA, USA). The amount of extracted RNA was quantified using a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). RNAs (50 ng) were reverse-transcribed to cDNAs, then amplified by single primer isothermal amplification. Finally, the amplified products (3.75 μg) were fragmented and biotin-labeled by Ovation RNA Amplification System V2 and FL-OvationTM cDNA Biotin Module V2 kits (NuGEN Technologies, San Carlos, CA, USA) according to the manufacturer's instructions. Labeled cDNAs were hybridized to an Affymetrix Mouse Genome 430A 2.0 Array and detected by the Microarray Core Facility at Dana-Farber Cancer Institute. The gene expression data were deposited in the European Bioinformatics Institute ArrayExpress database (http://www.ebi.ac.uk/ arrayexpress) with accession number E-MEXP-2072.
Data analysis
Data were analyzed by dChip (http://biosun1.harvard.edu/complab/dchip/) and GSEA 2.0 algorithm (http://www.broad.mit.edu/gsea/). With dChip, the raw expression data were normalized to account for differences in chip intensities and then filtered using 0.4ostandard deviation/meano1000, presence call% in the arrays used ⩾ 20% and the expression level ⩾ 20 in ⩾ 20% samples. Hierarchical clustering was performed among the filtered genes. For comparisons of gene expression between two groups, the transcripts were considered as upregulated or downregulated when their transcript levels in SALL4B Tg mice, as compared with multiple control animals, were increased or decreased more than 1.5-fold, P-valueo0.05 and lower confidence bound at 490%. 
MMC clonogenic assays
The MMC cologenic assays have been described previously for FA mice. 22 Briefly, BM cells were harvested from age-matched WT or SALL4B Tg mice. Low-density BM mononuclear cells were isolated by density gradient centrifugation using Histopaque 1.083 g/cm 3 (Sigma, St Louis, MO, USA). For clonogenic assays, 10 000 mononuclear cells were plated in triplicates in methylcellulose (Methocult; Stem Cell Technologies, Vancouver, BC, Canada) supplemented with 30% fetal calf serum, 2 mmol/l L-glutamine (Hyclone, Logan, UT, USA), 200 U/ml penicillin/streptomycin (Hyclone), 100 mmol/ l β-mercaptoethanol (Thermo Fisher, Waltham, MA, USA), 1% bovine serum albumin (Roche, Indianapolis, IN, USA), and 100 ng/ml recombinant rat stemcell factor, 100 ng/ml murine IL-3, 4 U/ml Epogen (Amgen, Thousand Oaks, CA, USA). Five or 20 μM of MMC (Bedford Laboratories, Bedford, OH, USA) were added. The plates were incubated for 7 days in a humidified atmosphere (37°C, 5% CO2), and colonies were counted on day 7.
Similarly, whole BM cells were harvested from age-matched WT or SALL4B Tg mice for MMC and/or ABT-737 colony-forming assay. A total of 10 000 mononuclear cells were plated out in triplicate in methylcellulose (MethoCult GF M3434; Stem Cell Technologies). The cells were treated with 50 nM of MMC alone (Bedford Laboratories), 0.3 μM or 1.0 μM of ABT-737 alone (provided by Abbott Laboratories, Abbott Park, IL, USA), 38 or MMC and ABT-737 together. The plates were incubated as above and colonies were counted on day 7.
Chromosomal spread BM cells were cultured the same way as described above for the MMC colony formation assay. At day 5, cultured BM cells were exposed to 50 nM of MMC and cultured for another 24 h. Before harvest, Colcemid was added to a final concentration of 0.1 ug/ml in for 45 min. Chromosome spreading was prepared for metaphase analysis as previously described. 39 HR and NHEJ reporter assay Lineage-negative SALL4B Tg and WT mouse BM cells and leukemia cell line KBM5 cells (a gift from Dr Ma's Lab, and used in our previous report 15 ) were used to perform HR and NHEJ reporter assays. [17] [18] [19] [20] [21] Plasmids containing HR or NHEJ reporter cassettes were linearized by I-SceI restriction enzyme (R0694L, NEB, Ipswich, MA, USA) and purified using QIAquick PCR Purification Kit (28106; Qiagen). Lineage-negative BM cells or KBM5 cells were electroporated with 0.5 μg of the NHEJ reporter construct or 2 μg of the HR reporter constructs, along with 0.1 μg of the tdTomato expression vector to normalize for differences in transfection efficiency. Electroporations were performed using the Amaxa Nucleofector (Walkersville, MD, USA). After transfection, lineage-negative cells were cultured in Serum-Free Expansion Medium (09600, Stem Cell Technologies) containing cytokines (10 ng/ml IL-3, 10 ng/ml IL-6, 50 ng/ml TPO and 50 ng/ml SCF). KBM5 cells were cultured in RPMI 1640 with 20% fetal bovine serum. GFP gene was normally inactive in the transfected HR or NHEJ constructs. Only when HR or NHEJ events have occurred, can an active GFP gene be reconstituted. Expression of GFP and Tomato was analyzed by fluorescence-activated cell-sorting analysis (BD FACSCalibur) 72 h after transfection. The ratio of GFP+ to Tomato+ cells was used as a measure for repair efficiency. 
Western blots of FANCD2
Whole-cell extracts were immunoblotted with anti-FANCD2 antibody (NB100-182, NOVUS, Littleton, CO, USA). The upper band (slightly larger form) is monoubiquitinated FANCD2 (FANCD2-L), and the lower band is unubiquitinated FANCD2 (FANCD2-S) . 40, 41 The ratio of FANCD2-L to FANCD2-S (L/S) was calculated by densitometry.
Primary human MDS/AML
The gene expression data on a cohort of 542 AML patients were downloaded from publicly available Gene Expression Omnibus (GEO) dataset under series accession number GSE13159. 25, 26 In addition, for our studies, we used primary human MDS/AML samples, which was described before. 11 Briefly, BM samples from 55 newly diagnosed MDS patients were collected in Beijing from December 2009 to December 2011. Another cohort of 20 MDS patient BM tissues was collected in Peking Union Medical College Hospital from 2013 to 2015 and used for analysis of SALL4 and TP53 protein expression. This study was approved by the institutional review board of Peking Union Medical College Hospital and informed consent was obtained from all subjects.
Immunohistochemistry staining of human MDS samples
Immunohistochemistry staining was performed on human MDS samples according to standard techniques as previously described. 12, 42 Briefly, paraffin-embedded sections were first de-paraffinized and hydrated. Then, the slides were microwaved in 10 mM sodium citrate for 15 min to retrieve the antigen. After cooling, the slides were blocked in PBST (PBS with 0.3% Triton) with 2% dry milk for 30 min. Tissue slides were then incubated with SALL4 antibody (ab29119, Abcam, Cambridge, MA, USA) or p53 (05-224, clone BP5312, Millipore, Billerica, MA, USA) overnight at room temperature. After three washes in PBST, slides were incubated with the secondary antibody (ZB-2301, ZSGB-BIO, Beijing, China) for 1 h at room temperature. After two more washes, the slides were incubated in Vectastain ABC reagent (Vector Laboratories, Burlingame, CA, USA) and developed in DAB solution. Hematoxylin (Fisher Scientific, Pittsburgh, PA, USA) was used to counterstain the slides. Cells were considered to be positive for SALL4 when they showed definitive nuclear staining.
Statistical analysis
Statistical analyses were performed using Graphpad Prism 5. P-values of o0.05 were considered statistically significant. Data were presented as means ± s.d. The variance between the groups that is in general similar being statistically compared. Unpaired t-test or Mann-Whitney test was used to study difference between two groups. Chi-Square test was used to analyze the correlation between SALL4 and TP53 expression.
